Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2025)
Inhibikase Therapeutics' (IKT) quarterly Interest Coverage Ratio came in at 1.79 in Q4 2025, up 99.37% on a QoQ basis from 282.66 in Q2 2025.
Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has 6 years of Interest Coverage Ratio data on file, last reported at 1.79 in Q4 2025.
- On a quarterly basis, Interest Coverage Ratio changed N/A year-over-year to 1.79 in Q4 2025; TTM through Dec 2025 was 6.75, a N/A change from a year earlier, with the FY2025 full-year figure at 1.64, down 78.59% from the prior year.
- Interest Coverage Ratio for Q4 2025 stood at 1.79, up from 282.66 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for IKT reached as high as 270.8 in Q4 2021 and fell as low as 28477.96 in Q3 2021.
- Historically, Interest Coverage Ratio has averaged 2826.9 across 5 years, with a median of 152.87 in 2023.
- On a YoY basis, Interest Coverage Ratio climbed as much as 260.99% in 2021 and fell as far as 29463.13% in 2021.
- Year by year, Interest Coverage Ratio stood at 270.8 in 2021, then slumped by 123.71% to 64.2 in 2022, then plunged by 130.15% to 147.76 in 2023, then jumped by 74.27% to 38.02 in 2024, then soared by 95.29% to 1.79 in 2025.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 1.79 in Q4 2025, 282.66 in Q2 2025, and 7798.08 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.79 |
| Jun 30, 2025 | -282.66 |
| Mar 31, 2025 | -7,798.08 |
| Sep 30, 2024 | -38.02 |
| Jun 30, 2024 | -26.51 |
| Mar 31, 2024 | -261.13 |
| Sep 30, 2023 | -147.76 |
| Jun 30, 2023 | -152.87 |
| Mar 31, 2023 | -94.88 |
| Sep 30, 2022 | -64.20 |
| Mar 31, 2022 | -4,769.37 |
| Dec 31, 2021 | 270.80 |
| Sep 30, 2021 | -28,477.96 |
| Jun 30, 2021 | -336.50 |
| Mar 31, 2021 | -222.54 |
| Dec 31, 2020 | -168.21 |
| Sep 30, 2020 | -96.33 |
| Jun 30, 2020 | -52.08 |
| Mar 31, 2020 | -72.73 |